Abed et al
Adapting gradually is key in finding the balance between efficacy and tolerability
van der Klaauw AA, Croizier S, Mendes de Oliveira E, Stadler LKJ, Park S, Kong Y, Banton MC, Tandon P, Hendricks AE, Keogh JM, Riley SE, Papadia S, Henning E, Bounds R, Bochukova EG, Mistry V, O'Rahilly S, Simerly RB, Minchin JEN, Barroso I, Jones EY, Bouret SG, Farooqi IS
248 (3 pt 1): G3139 Rebouche C, Mack D, Edmonson P
Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation
For patients throughout Orange County, alcohol tolerance, appetite changes, side effects, and metabolic health concerns are all important details to review as part of a thoughtful treatment plan